Leerink Partnrs Equities Analysts Lower Earnings Estimates for Tandem Diabetes Care, Inc. (NASDAQ:TNDM)

Tandem Diabetes Care, Inc. (NASDAQ:TNDM - Free Report) - Analysts at Leerink Partnrs decreased their FY2028 earnings per share estimates for Tandem Diabetes Care in a research report issued on Thursday, March 28th. Leerink Partnrs analyst M. Kratky now expects that the medical device company will earn $0.50 per share for the year, down from their prior forecast of $0.51. The consensus estimate for Tandem Diabetes Care's current full-year earnings is ($1.62) per share.

Other analysts have also recently issued research reports about the stock. StockNews.com raised shares of Tandem Diabetes Care from a "sell" rating to a "hold" rating in a report on Thursday, March 21st. Citigroup lifted their price target on shares of Tandem Diabetes Care from $25.00 to $31.00 and gave the stock a "neutral" rating in a research note on Friday, March 15th. Finally, Stifel Nicolaus upgraded shares of Tandem Diabetes Care from a "hold" rating to a "buy" rating and upped their price objective for the company from $24.00 to $37.00 in a research note on Tuesday. One research analyst has rated the stock with a sell rating, seven have issued a hold rating and five have issued a buy rating to the stock. According to MarketBeat.com, Tandem Diabetes Care presently has a consensus rating of "Hold" and an average target price of $36.36.

Tandem Diabetes Care Stock Up 0.3 %

Shares of NASDAQ:TNDM traded up $0.11 on Friday, hitting $35.41. 1,809,821 shares of the company's stock were exchanged, compared to its average volume of 2,376,517. Tandem Diabetes Care has a 1-year low of $13.82 and a 1-year high of $43.51. The company has a market capitalization of $2.32 billion, a PE ratio of -10.29 and a beta of 1.08. The company has a debt-to-equity ratio of 0.91, a quick ratio of 3.02 and a current ratio of 3.83. The firm's 50-day moving average is $26.97 and its 200 day moving average is $23.67.

Tandem Diabetes Care (NASDAQ:TNDM - Get Free Report) last released its earnings results on Wednesday, February 21st. The medical device company reported ($0.27) EPS for the quarter, missing the consensus estimate of ($0.23) by ($0.04). The company had revenue of $196.80 million for the quarter, compared to analyst estimates of $204.86 million. Tandem Diabetes Care had a negative return on equity of 31.48% and a negative net margin of 29.77%.

Hedge Funds Weigh In On Tandem Diabetes Care

A number of large investors have recently bought and sold shares of TNDM. RiverPark Advisors LLC acquired a new stake in shares of Tandem Diabetes Care in the 4th quarter valued at approximately $27,000. State of Wyoming lifted its holdings in Tandem Diabetes Care by 45.8% in the fourth quarter. State of Wyoming now owns 821 shares of the medical device company's stock valued at $37,000 after acquiring an additional 258 shares during the period. Signaturefd LLC boosted its position in shares of Tandem Diabetes Care by 871.8% during the 4th quarter. Signaturefd LLC now owns 1,691 shares of the medical device company's stock worth $50,000 after purchasing an additional 1,517 shares in the last quarter. PNC Financial Services Group Inc. boosted its position in shares of Tandem Diabetes Care by 51.7% during the 3rd quarter. PNC Financial Services Group Inc. now owns 3,226 shares of the medical device company's stock worth $67,000 after purchasing an additional 1,099 shares in the last quarter. Finally, GAMMA Investing LLC acquired a new position in shares of Tandem Diabetes Care during the 4th quarter worth $73,000.

About Tandem Diabetes Care

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.